Orgenesis Inc. (ORGS)
OTCMKTS
· Delayed Price · Currency is USD
2.320
-1.050 (-31.16%)
Mar 31, 2025, 1:17 PM EST
Orgenesis Revenue
Orgenesis had revenue of $347.00K in the quarter ending September 30, 2024, with 215.45% growth. This brings the company's revenue in the last twelve months to $899.00K, down -93.57% year-over-year. In the year 2023, Orgenesis had annual revenue of $530.00K, down -98.53%.
Revenue (ttm)
899.00K
Revenue Growth
-93.57%
P/S Ratio
13.88
Revenue / Employee
6.16K
Employees
146
Market Cap
18.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 530.00K | -35.50M | -98.53% |
| Dec 31, 2022 | 36.03M | 523.00K | 1.47% |
| Dec 31, 2021 | 35.50M | 27.85M | 363.96% |
| Dec 31, 2020 | 7.65M | 3.75M | 96.26% |
| Dec 31, 2019 | 3.90M | -18.33M | -82.46% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Nov 30, 2017 | Pro | Pro | Pro |
| Nov 30, 2016 | Pro | Pro | Pro |
| Nov 30, 2015 | Pro | Pro | Pro |
| Nov 30, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| SS Innovations International | 16.04M |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| American Oncology Network | 1.76B |
Orgenesis News
- 24 days ago - Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies - Accesswire
- 2 months ago - Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings - Accesswire
- 4 months ago - Orgenesis GAAP EPS of $1.93, revenue of $0.3M - Seeking Alpha
- 6 months ago - Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga
- 6 months ago - Orgenesis announces 1-for-10 reverse stock split to regain Nasdaq compliance - Seeking Alpha
- 7 months ago - Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia - GlobeNewsWire
- 8 months ago - Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally - GlobeNewsWire
- 11 months ago - Orgenesis Provides Business Update for the First Quarter of 2024 - GlobeNewsWire